专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011161253A1 EDITING PROFILING OF PDE8A PRE -MRNA : USE AS SPECIFIC BIOMARKER OF ADARS ACTIVITIES IN HUMAN TISSUES TO DIAGNOSE AND TO PREDICT AND ASSESS THERAPEUTIC EFFICACY AND/OR EFFICIENCY OR POTENTIAL DRUG SIDE EFFECTS 审中-公开
标题翻译： PDE8A PRE-MRNA的编辑概况：用作人体组织中ADARS活动的特定生物标志物，用于诊断和预测和评估治疗效果和/或效率或潜在药物副作用
公开(公告)号：WO2011161253A1
公开(公告)日：2011-12-29
申请号：PCT/EP2011/060644
申请日：2011-06-24
申请人： BIOCORTECH , WEISSMANN, Dinah , PUJOL, Jean-François , CAVAREC, Laurent , VINCENT, Laurent
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , CAVAREC, Laurent , VINCENT, Laurent
IPC分类号： C12Q1/68 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q1/34 , C12Q2600/106 , C12Q2600/136 , C12Q2600/142 , C12Q2600/158 , G01N33/5023 , G01N2333/978 , G01N2800/28 , G01N2800/2821 , G01N2800/2857 , G01N2800/30 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to the use of the editing profile of PDE8A pre-mRNA as a specific bio marker of ADARs activities in evolved primate, particularly in Human tissues. The present invention also relates to an in vitro method for predicting in Human an alteration of the mechanism of the ADARs catalysed pre-mRNA editing of target genes, by analysing the PDE8A pre-mRNA editing profile in a peripheral tissue sample containing cells expressing said PDE8A pre-mRNA, such as blood sample. The present invention is also directed to an in vitro method for the screening of potential therapeutic compound and to predict and assess therapeutic efficacy and/or efficiency or to diagnose potential severe brain or peripheral drug side effects implementing said PDE8A pre-mRNA editing profile as specific biomarker. The present invention is further directed to a method for determining the PDE8A pre-mRNA editing profile in Human, particularly by capillary electrophoresis single-strand conformation polymorphism (CE-SSCP) method after amplification by a nested PCR. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR and kit comprising such sets of primers and human cells capable of expressing PDE8A and ADARs.
摘要翻译：本发明涉及PDE8A前mRNA的编辑概况在进化灵长类动物中特别是ADARs活性的特异性生物标记物的使用，特别是在人组织中。本发明还涉及通过在含有表达所述PDE8A的细胞的外周组织样品中分析PDE8A前mRNA编码谱的方法，在人类中预测ADAR催化的靶基因前mRNA编辑机制的改变前mRNA，如血液样品。本发明还涉及用于筛选潜在治疗化合物并预测和评估治疗功效和/或效率或用于诊断实施所述PDE8A前mRNA编辑简档作为具体的潜在严重脑或外周药物副作用的体外方法生物标志物。本发明还涉及一种通过巢式PCR扩增后，特别是通过毛细管电泳单链构象多态性（CE-SSCP）方法测定人类PDE8A前mRNA编码特征的方法。最后，本发明涉及在所述巢式PCR中实施的特定核酸引物和包含能够表达PDE8A和ADAR的这样一组引物和人细胞的试剂盒。

2. 发明申请

WO2008152146A1 PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS 审中-公开
标题翻译：包含表达5HTR2C和/或ADARS的细胞的外周组织样品作为改变5HTR2C MRNA编码机制的标记及其应用
公开(公告)号：WO2008152146A1
公开(公告)日：2008-12-18
申请号：PCT/EP2008/057519
申请日：2008-06-13
申请人： BIOCORTECH , WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent , MANN, John
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent , MANN, John
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/6896 , G01N33/942
摘要： The present invention relates to an in vitro method for predicting a pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing, particularly the serotonin 2C receptor (5HTR2C), in a patient from a peripherical tissue sample containing cells expressing said mRNA, such as the 5HTR2C mRNA, and/or adenosine deaminases acting on RNA (ADARs), such as skin and/or blood tissue sample. The present invention further comprises a method for identifying if an agent is capable of in vivo modifying the editing of the 5HTR2C mRNA in brain tissue or to control the efficiency of a drug intended to prevent or to treat a pathology related to an alteration of the mechanism of the 5HTR2C mRNA editing brain tissue, these methods comprising the implementation of said peripherical tissue markers. In a particular aspect, the present invention relates to such methods wherein the 5HTR2C mRNA editing rate or profile, when it is necessary, is determined by a single strand conformation polymorphism (SSCP) method after amplification by a PCR, preferably by a nested PCR, of the specific mRNA fragment containing the edition sites, making it possible, under given analytical conditions, to obtain the editing rate and/or profile of this edited 5HTR2C mRNA from said peripherical tissue. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR.
摘要翻译：本发明涉及一种用于预测来自外周组织样品的患者中ADAR依赖性A至I mRNA编辑的mRNA编辑，特别是5-羟色胺2C受体（5HTR2C）的mRNA编辑的机制的改变的病理学的体外方法含有表达所述mRNA的细胞，例如5HTR2C mRNA，和/或作用于RNA（ADAR）的腺苷脱氨酶，例如皮肤和/或血液组织样品。本发明还包括用于鉴定药物是否能够体内修饰脑组织中的5HTR2C mRNA的编辑或控制旨在预防或治疗与机制改变有关的病理学的效力的方法的5HTR2C mRNA编辑脑组织，这些方法包括实施所述外周组织标记物。在特定方面，本发明涉及这样的方法，其中当需要时，通过PCR扩增后优选通过巢式PCR，通过单链构象多态性（SSCP）方法确定5HTR2C mRNA编辑速率或分布，的具有编码位点的特异性mRNA片段，使得在给定的分析条件下可以从所述外周组织获得该编辑的5HTR2C mRNA的编辑率和/或分布。最后，本发明涉及在所述巢式PCR中实施的特定核酸引物。

3. 发明申请

WO2010070074A2 EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM 审中-公开
标题翻译：评估药物诱发的肌肉障碍和副作用的潜在风险：使用专用平台
公开(公告)号：WO2010070074A2
公开(公告)日：2010-06-24
申请号：PCT/EP2009/067464
申请日：2009-12-17
申请人： BIOCORTECH , WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent
IPC分类号： C12Q1/68 , G01N33/573
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/142 , C12Q2600/158 , G01N33/5014 , G01N33/5058 , G01N33/942 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to in vitro methodsfor the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing of the serotonin 2C receptor (5HTR2C). Finally, the present invention is directed to the kits and tools for the implementation of these methods. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile or the screening of compounds involved in drug development and/or in pharmaceutical compositions.
摘要翻译：本发明涉及测定化合物潜在毒性的体外方法。本发明还包括用于选择治疗化合物的治疗化合物的方法，所述治疗化合物可用于治疗与改变血清素2C受体（5HTR2C）的ADAR依赖性A至I mRNA编辑的mRNA编辑机制相关的病理学。最后，本发明涉及用于实施这些方法的套件和工具。本发明在制药工业中用于分析涉及药物开发和/或药物组合物的化合物的毒性特征或筛选。

4. 发明申请

WO2005059123A2 NOVEL PP2A/BGAMMA SUBUNITS, MODULATORS THEREOF, AND THEIR USES IN THE TREATMENT OF MENTAL DISORDERS 审中-公开
标题翻译：新型PP2A / BGAMMA亚基，其调节剂及其在治疗精神障碍中的应用
公开(公告)号：WO2005059123A2
公开(公告)日：2005-06-30
申请号：PCT/EP2004/053512
申请日：2004-12-15
申请人： Ares Trading S.A. , CHUMAKOV, Ilya , GREL, Pascale , CAVAREC, Laurent
发明人： CHUMAKOV, Ilya , GREL, Pascale , CAVAREC, Laurent
IPC分类号： C12N9/00
CPC分类号： C07K14/4702 , A61K48/00 , C12N9/16
摘要： This invention is in the field of mental disorders such as bipolar disorder, schizophrenia, depression and other mood disorders. More specifically, this invention relates to novel PP2A/Bγ subunits that are generated by alternative splicing events. The invention also relates the use of the novel PP2ABγ subunits for screening for modulators, and to the use of said modulators for treating said mental disorders.
摘要翻译：本发明涉及精神障碍，如双相性精神障碍，精神分裂症，抑郁症和其他情绪障碍。更具体地，本发明涉及通过选择性剪接事件产生的新型PP2A / Bgamma亚基。本发明还涉及新型PP2ABgamma亚基用于筛选调节剂的用途，以及所述调节剂用于治疗所述精神障碍的用途。

5. 发明申请

WO2004000875A3 NOVEL KCNQ POLYPEPTIDES, MODULATORS THEREOF, AND THEIR USES IN THE TREATMENT OF MENTAL DISORDERS 审中-公开
公开(公告)号：WO2004000875A3
公开(公告)日：2003-12-31
申请号：PCT/EP2003/050246
申请日：2003-06-20
申请人： GENSET SA , CAVAREC, Laurent , CHUMAKOV, Ilya , DESTENAVES, Benoit , GONTHIER, Catherine , ELIAS, Isabelle
发明人： CAVAREC, Laurent , CHUMAKOV, Ilya , DESTENAVES, Benoit , GONTHIER, Catherine , ELIAS, Isabelle
IPC分类号： C07K7/00
摘要： The invention encompasses polypeptides and polynucleotides of three novel bipolar disorder-associated potassium channel polypeptides, KCNQ2-15bx, KCNQ2-15by and KCNQ2-15bz. The invention further relates to the use of potassium channels comprising KCNQ2 subunits for screening for modulators thereof, the use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators. The invention also discloses biallelic markers located in the KCNQ2 gene and their use for diagnosing mental disorders.

6. 发明公开

EP2162550A1 PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS 失效转让
标题翻译：与5HTR2C AND / OR ADAR表达细胞作为标记修订5HTR2C体mRNA加工及其应用的机制外周组织样本
公开(公告)号：EP2162550A1
公开(公告)日：2010-03-17
申请号：EP08761038.2
申请日：2008-06-13
申请人： Biocortech
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent , MANN, John
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/6896 , G01N33/942
摘要： The present invention relates to an in vitro method for predicting a pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing, particularly the serotonin 2C receptor (5HTR2C), in a patient from a peripherical tissue sample containing cells expressing said mRNA, such as the 5HTR2C mRNA, and/or adenosine deaminases acting on RNA (ADARs), such as skin and/or blood tissue sample. The present invention further comprises a method for identifying if an agent is capable of in vivo modifying the editing of the 5HTR2C mRNA in brain tissue or to control the efficiency of a drug intended to prevent or to treat a pathology related to an alteration of the mechanism of the 5HTR2C mRNA editing brain tissue, these methods comprising the implementation of said peripherical tissue markers. In a particular aspect, the present invention relates to such methods wherein the 5HTR2C mRNA editing rate or profile, when it is necessary, is determined by a single strand conformation polymorphism (SSCP) method after amplification by a PCR, preferably by a nested PCR, of the specific mRNA fragment containing the edition sites, making it possible, under given analytical conditions, to obtain the editing rate and/or profile of this edited 5HTR2C mRNA from said peripherical tissue. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR.

7. 发明公开

EP2585613A1 EDITING PROFILING OF PDE8A PRE -MRNA : USE AS SPECIFIC BIOMARKER OF ADARS ACTIVITIES IN HUMAN TISSUES TO DIAGNOSE AND TO PREDICT AND ASSESS THERAPEUTIC EFFICACY AND/OR EFFICIENCY OR POTENTIAL DRUG SIDE EFFECTS 有权转让
标题翻译：配置文件创建PDE8A前体mRNA：使用ADAR锻炼作为特异性标志物在人体组织进行诊断和预测评价治疗效果和/或效率的药物或副作用可能性
公开(公告)号：EP2585613A1
公开(公告)日：2013-05-01
申请号：EP11727197.3
申请日：2011-06-24
申请人： Biocortech
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , CAVAREC, Laurent , VINCENT, Laurent
IPC分类号： C12Q1/68 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q1/34 , C12Q2600/106 , C12Q2600/136 , C12Q2600/142 , C12Q2600/158 , G01N33/5023 , G01N2333/978 , G01N2800/28 , G01N2800/2821 , G01N2800/2857 , G01N2800/30 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to the use of the editing profile of PDE8A pre-mRNA as a specific bio marker of ADARs activities in evolved primate, particularly in Human tissues. The present invention also relates to an in vitro method for predicting in Human an alteration of the mechanism of the ADARs catalysed pre-mRNA editing of target genes, by analysing the PDE8A pre-mRNA editing profile in a peripheral tissue sample containing cells expressing said PDE8A pre-mRNA, such as blood sample. The present invention is also directed to an in vitro method for the screening of potential therapeutic compound and to predict and assess therapeutic efficacy and/or efficiency or to diagnose potential severe brain or peripheral drug side effects implementing said PDE8A pre-mRNA editing profile as specific biomarker. The present invention is further directed to a method for determining the PDE8A pre-mRNA editing profile in Human, particularly by capillary electrophoresis single-strand conformation polymorphism (CE-SSCP) method after amplification by a nested PCR. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR and kit comprising such sets of primers and human cells capable of expressing PDE8A and ADARs.

8. 发明公开

EP2376649A2 EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM 有权转让
标题翻译：评价药物引起的情绪障碍和自杀的潜在危险的：使用专用平台的
公开(公告)号：EP2376649A2
公开(公告)日：2011-10-19
申请号：EP09775225.7
申请日：2009-12-17
申请人： Biocortech
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent
IPC分类号： C12Q1/68 , G01N33/573
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/142 , C12Q2600/158 , G01N33/5014 , G01N33/5058 , G01N33/942 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to in vitro methods for the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing of the serotonin 2C receptor (5HTR2C). Finally, the present invention is directed to the kits and tools for the implementation of these methods. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile or the screening of compounds involved in drug development and/or in pharmaceutical compositions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式